Biosimilars: complements and comments on the recent statement of the SFR and CRI. Comment on: “Biosimilars: An opportunity. Position statement of the French Rheumatology Society (SFR) and Inflammatory Rheumatic Disease Club (CRI).” Schaeverbeke et al. Joint Bone Spine 2018;95:399-402

‘To switch or not to switch’: the missing piece in the puzzle of biosimilar literature?

“…Two strategies for the use of biosimilars can be differentiated in patients already treated with an originator: mandatory switch or physician–patient shared decision. Physician–patient shared decision has been favored by rheumatology scientific societies, by an international consensus group and by patients association 6–8. Indeed, real-life studies reporting the acceptance of the switch from OE to SB4 in case of shared decision together with an optimised communication strategy have reported acceptance rates of 92%–99% 9 10.…”